Biomarker Analysis Services for Overactive Bladder
Ace Therapeutics offers specialized biomarker analysis services exclusively dedicated to supporting drug discovery and preclinical development for overactive bladder research. Our comprehensive biomarker panel is designed to provide deep insights into the molecular and cellular mechanisms underlying overactive bladder, enabling a robust understanding of disease pathophysiology. Please note that all services are strictly focused on research applications for drug discovery and do not include clinical diagnostic or patient testing services.
Effective therapeutic intervention begins with the precise identification of relevant biomarkers. At Ace Therapeutics, our biomarker discovery services are tailored to accelerate the early phases of drug development for overactive bladder. We employ systematic approaches to identify, screen, and validate candidate biomarkers associated with disease mechanisms. Our process integrates literature mining, in silico analysis, and experimental validation to build a solid foundation for downstream therapeutic development. Rigorous screening and validation protocols ensure that only the most promising biomarker candidates are advanced for further study.
Multi Omics: Our multi-omics approach leverages cutting-edge technologies across genomics, transcriptomics, proteomics, and metabolomics to enable a holistic study of biological systems relevant to overactive bladder. By integrating data from DNA, RNA, protein, and metabolite analyses, we provide comprehensive profiling of disease-associated pathways. This enables the identification of molecular signatures and potential biomarkers involved in neurotransmission, inflammation, smooth muscle function, and purinergic signaling—key processes implicated in overactive bladder pathophysiology.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves a combination of experimental and analytical strategies to assess the association of each candidate with overactive bladder pathophysiology. Preliminary screening includes quantitative and qualitative analyses in relevant biological models and sample types. Promising candidates are prioritized based on criteria such as specificity, biological relevance, and detectability in accessible matrices. This rigorous approach ensures that only biomarkers with strong potential for research utility in overactive bladder are advanced.
Diverse Technological Platforms: Our laboratory is equipped to develop and adapt custom assays across a range of technological platforms. We tailor assay development to the unique requirements of each biomarker and research project, ensuring optimal sensitivity, specificity, and throughput. Platforms include immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging systems.
Immunoassays: We offer a suite of immunoassay platforms, including ELISA, chemiluminescent immunoassays, and multiplex bead-based assays, for the sensitive and specific quantification of protein biomarkers.
Mass Spectrometry: Our mass spectrometry services utilize LC-MS/MS for high-resolution, quantitative analysis of proteins, peptides, and small molecule biomarkers.
Flow Cytometry: Flow cytometry enables the characterization and quantification of cell-surface and intracellular markers in heterogeneous cell populations relevant to overactive bladder research.
Molecular Diagnostics: We apply molecular diagnostic techniques such as qPCR, digital PCR, and next-generation sequencing for the detection and quantification of nucleic acid biomarkers.
Histopathology And Imaging: Advanced histopathology and imaging platforms provide spatial and morphological context for biomarker expression in tissue samples, supporting in-depth mechanistic studies.
Rigorous Method Validation: All analytical methods undergo a rigorous validation process in accordance with established research guidelines. Validation parameters include accuracy, precision, sensitivity, specificity, linearity, and reproducibility. Comprehensive quality control measures are implemented at every stage to ensure the reliability and robustness of assay performance, supporting high-quality research outcomes.
Our quantitative analysis capabilities enable precise measurement of biomarker levels in a variety of biological matrices. We employ state-of-the-art analytical techniques to deliver reliable, reproducible, and interpretable data that inform preclinical drug development decisions for overactive bladder.
Sample Analysis: We handle a diverse range of sample types, including tissue, plasma, serum, urine, and cell lysates. All samples are processed using standardized protocols to maintain integrity and consistency. Stringent quality control procedures are applied throughout the analysis workflow to ensure data validity and reproducibility.
High Throughput Capabilities: Ace Therapeutics utilizes multiplexed analytical platforms to support high-throughput biomarker analysis. These technologies enable simultaneous measurement of multiple biomarkers from minimal sample volumes, increasing efficiency and conserving valuable research specimens. High-throughput capabilities accelerate discovery timelines and facilitate large-scale exploratory studies.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| adrenoceptor alpha 1D (ADRA1D) | Adrenoceptor alpha 1D (ADRA1D) is a member of the alpha-1 adrenergic receptor family, which are G protein-coupled receptors (GPCRs) that mediate the physiological effects of the catecholamines norepinephrine and epinephrine. ADRA1D primarily couples to the Gq/11 family of G proteins, leading to activation of phospholipase C, increased intracellular calcium, and subsequent smooth muscle contraction. It is expressed in various tissues, including vascular smooth muscle, the prostate, and the central nervous system. ADRA1D plays a role in regulating vascular tone, blood pressure, and certain aspects of urinary tract function. | ADRA1D expression and genetic variants have been investigated as potential biomarkers in several contexts. Its expression levels have been studied in relation to prostate cancer, benign prostatic hyperplasia, and certain cardiovascular diseases. In these settings, ADRA1D has been evaluated for its association with disease presence, progression, or response to therapy. Additionally, its expression in vascular tissues has been explored in studies of hypertension and vascular remodeling. |
| adrenoceptor beta 3 (ADRB3) | The adrenoceptor beta 3 (ADRB3) gene encodes the beta-3 adrenergic receptor, which is a member of the G protein-coupled receptor family. This receptor is primarily expressed in adipose tissue, where it mediates the catecholamine-induced activation of adenylate cyclase through the Gs protein. Activation of ADRB3 stimulates lipolysis and thermogenesis, contributing to the regulation of energy expenditure and fat metabolism. It also plays a role in smooth muscle relaxation in various tissues, including the urinary bladder. The receptor is involved in metabolic processes such as glucose homeostasis and has been studied in the context of obesity, type 2 diabetes, and metabolic syndrome. | ADRB3 has been investigated as a biomarker in metabolic and obesity-related conditions. Genetic variants, particularly the Trp64Arg polymorphism, have been studied for associations with obesity, insulin resistance, type 2 diabetes, and altered lipid metabolism. Expression levels and genetic polymorphisms of ADRB3 have been evaluated for their potential to inform risk stratification, disease susceptibility, and therapeutic response in metabolic disorders. Additionally, ADRB3 expression in bladder tissue has been explored in the context of overactive bladder and related urological conditions. |
| cholinergic receptor muscarinic 2 (CHRM2) | The cholinergic receptor muscarinic 2 (CHRM2) is a member of the G protein-coupled receptor (GPCR) family that binds the neurotransmitter acetylcholine. CHRM2 is primarily expressed in the heart, central nervous system, and various smooth muscles. In the heart, CHRM2 mediates the inhibitory effects of acetylcholine on cardiac function, including slowing the heart rate and reducing contractility via Gi protein-mediated inhibition of adenylate cyclase and decreased cyclic AMP levels. In the central nervous system, CHRM2 modulates neurotransmitter release, synaptic plasticity, and neuronal excitability, playing roles in cognitive processes, memory, and attention. The receptor's activity is essential for parasympathetic nervous system signaling and homeostatic regulation of multiple physiological functions. | CHRM2 expression and genetic variants have been studied as biomarkers in several contexts. In neuropsychiatric research, alterations in CHRM2 expression or polymorphisms have been investigated in relation to conditions such as major depressive disorder, schizophrenia, and bipolar disorder. In cardiovascular research, CHRM2 has been examined for its role in cardiac function and arrhythmias. Additionally, CHRM2 has been explored in pharmacogenomic studies to assess individual variations in response to anticholinergic drugs. Most applications involve its use as a candidate biomarker for disease susceptibility, progression, or therapeutic response in neurological and cardiovascular disorders. |
| cholinergic receptor muscarinic 3 (CHRM3) | The cholinergic receptor muscarinic 3 (CHRM3) is a G protein-coupled receptor that binds acetylcholine, a key neurotransmitter in the parasympathetic nervous system. Upon activation, CHRM3 primarily couples to Gq/11 proteins, leading to the activation of phospholipase C, increased intracellular calcium levels, and stimulation of downstream signaling pathways. CHRM3 is widely expressed in smooth muscle, exocrine glands, and various regions of the central nervous system. It mediates smooth muscle contraction, glandular secretion (such as in salivary and sweat glands), and plays roles in cognitive and autonomic functions. | CHRM3 expression and activity have been investigated as potential biomarkers in several contexts. Altered CHRM3 levels have been reported in certain cancers, such as bladder and colorectal cancer, where its expression may correlate with tumor progression or aggressiveness. In addition, CHRM3 has been studied in relation to neurological disorders, including Alzheimer's disease, due to its role in cholinergic neurotransmission. Its expression in tissues or fluids can be assessed to provide information on disease state, progression, or response to therapy in these contexts. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, as well as other cell types including monocytes, dendritic cells, and epithelial cells. It is synthesized as an inactive precursor (pro-IL1B) and is cleaved into its active form by caspase-1 within the inflammasome complex. IL1B plays a central role in the regulation of immune and inflammatory responses. It promotes the expression of adhesion molecules on endothelial cells, stimulates the production of other cytokines and chemokines, induces fever by acting on the hypothalamus, and contributes to the activation and recruitment of immune cells to sites of infection or injury. IL1B is also involved in tissue remodeling, bone resorption, and can influence cell proliferation and apoptosis. | IL1B is commonly measured in biological fluids such as blood, serum, plasma, or synovial fluid to assess the presence and degree of inflammation. Elevated levels of IL1B have been observed in various inflammatory and autoimmune conditions, including rheumatoid arthritis, sepsis, and inflammatory bowel disease. Its quantification is used in research and clinical studies to monitor inflammatory status, evaluate disease activity, and investigate the response to anti-inflammatory therapies. |
| nerve growth factor (NGF) | Nerve growth factor (NGF) is a neurotrophin that plays a crucial role in the growth, maintenance, and survival of certain target neurons, particularly sympathetic and sensory neurons. NGF binds primarily to the TrkA (tropomyosin receptor kinase A) receptor and the p75 neurotrophin receptor, initiating signaling cascades that promote neuronal differentiation, survival, and axonal growth. Beyond its effects on neurons, NGF is also involved in regulating immune responses, inflammation, and tissue repair processes. NGF expression is modulated in response to injury or inflammation, and it has been implicated in the development and maintenance of both the central and peripheral nervous systems. | NGF has been studied as a biomarker in various contexts, including neurodegenerative diseases, chronic pain conditions, and inflammatory disorders. Altered levels of NGF in biological fluids such as serum, plasma, or cerebrospinal fluid have been associated with conditions such as Alzheimer's disease, peripheral neuropathies, and chronic pain syndromes. In addition, NGF concentrations have been measured in inflammatory diseases like asthma and arthritis. Its measurement is used in research settings to assess disease presence, progression, or response to therapeutic interventions. |
| phosphodiesterase 5A (PDE5A) | Phosphodiesterase 5A (PDE5A) is an enzyme that specifically hydrolyzes cyclic guanosine monophosphate (cGMP) to 5'-GMP, thereby regulating intracellular levels of cGMP. cGMP is a secondary messenger involved in various physiological processes, including smooth muscle relaxation, vasodilation, and inhibition of platelet aggregation. PDE5A is highly expressed in vascular smooth muscle, particularly in the corpus cavernosum of the penis, as well as in the lung, platelets, and other tissues. By modulating cGMP signaling, PDE5A plays a critical role in the regulation of vascular tone and blood flow. | PDE5A expression and activity have been studied as potential biomarkers in several contexts, including cardiovascular diseases such as pulmonary arterial hypertension and heart failure, as well as erectile dysfunction. Altered PDE5A levels or activity may reflect changes in cGMP signaling pathways associated with these conditions. Measurement of PDE5A, particularly in tissue or plasma, has been explored for its potential to assist in disease characterization, therapeutic response monitoring, and stratification of patients for treatment with PDE5 inhibitors. |
| purinergic receptor P2X 2 (P2RX2) | Purinergic receptor P2X 2 (P2RX2) is a member of the P2X family of ligand-gated ion channels, which are activated by extracellular adenosine triphosphate (ATP). P2RX2 forms homo- or heterotrimeric complexes that function as non-selective cation channels, permitting the influx of sodium, potassium, and calcium ions upon ATP binding. It is widely expressed in neuronal tissues, particularly in sensory and autonomic ganglia, and plays a significant role in synaptic transmission, modulation of neuronal excitability, and sensory signal processing, including auditory transduction in the cochlea. P2RX2-mediated signaling is involved in neurotransmitter release, neuronal development, and responses to tissue injury or inflammation. | P2RX2 expression and function have been investigated in the context of auditory function, particularly in relation to hereditary and acquired forms of hearing loss. Mutations in the P2RX2 gene have been associated with autosomal dominant nonsyndromic hearing loss (DFNA41). Assessment of P2RX2 status may be informative in genetic studies of hearing impairment and in research examining purinergic signaling in sensory systems. Additionally, altered P2RX2 expression has been explored in studies of inflammation and neuropathic pain, where it may serve as an indicator of purinergic signaling activity. |
| purinergic receptor P2X 3 (P2RX3) | Purinergic receptor P2X 3 (P2RX3) is a member of the P2X family of ligand-gated ion channels that are activated by extracellular ATP. P2RX3 is predominantly expressed in sensory neurons, especially those of the dorsal root and trigeminal ganglia. Upon activation by ATP, the receptor forms a non-selective cation channel that permits the influx of sodium and calcium ions, leading to membrane depolarization and neuronal excitation. P2RX3 plays a critical role in the transmission of nociceptive (pain-related) signals, particularly those arising from tissue injury or inflammation. It is also implicated in mechanosensation and visceral sensory pathways. | P2RX3 has been studied as a biomarker for sensory neuron activity and pain signaling, particularly in conditions associated with chronic pain, neuropathic pain, and visceral hypersensitivity. Altered expression or function of P2RX3 has been observed in tissues from patients with chronic cough, interstitial cystitis/bladder pain syndrome, and other pain-related disorders. Its presence and activity may be used to characterize disease states involving aberrant sensory neuron signaling or to assess the potential efficacy of therapeutic interventions targeting purinergic signaling pathways. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as by a variety of other immune and non-immune cells. TNF plays a central role in regulating immune responses, inflammation, and apoptosis. It exerts its effects by binding to two distinct receptors, TNFR1 and TNFR2, activating downstream signaling pathways such as NF-κB and MAPKs. These pathways mediate the expression of genes involved in cell survival, differentiation, and inflammatory responses. TNF is involved in host defense against infections, the induction of fever, and the modulation of immune cell activity. Dysregulation of TNF production or signaling has been implicated in the pathogenesis of several inflammatory and autoimmune diseases. | TNF has been utilized as a biomarker for the assessment of inflammatory activity in various clinical settings. Elevated levels of TNF in blood, tissue, or other biological fluids have been associated with diseases characterized by inflammation, such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. Measurement of TNF concentrations can provide information about the presence and severity of inflammation, and changes in TNF levels may be monitored to evaluate disease progression or response to therapy. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services offer a comprehensive suite of capabilities for the identification, validation, and analysis of molecular targets relevant to overactive bladder. All biomarkers discussed are research targets only; we do not claim any biomarker as validated or mandatory for any application. Our focus is exclusively on exploratory research and preclinical development, and we maintain strict scientific objectivity throughout all projects.
We invite you to engage with Ace Therapeutics to discuss exploratory biomarker research for overactive bladder. Our team is dedicated to scientific collaboration, knowledge exchange, and advancing preclinical research through objective and rigorous analysis. Connect with us to explore how our expertise can support your research goals.
Make Order
Experimental Scheme
Implementation
Conclusion
